Q-omics provides the consensus-scored RPL26P34 profile across patient tissues and cancer cell-line models. RPL26P34 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPL26P34 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, RPL26P34 RNA expression shows 5,921 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, BRCA, and STAD as cancer lineages where RPL26P34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL26P34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL26P34 survival associations across molecular data types. RPL26P34 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL26P34 RNA expression–survival associations across cancer types. High RPL26P34 expression shows unfavorable associations in UVM, THYM, PAAD, LUAD, KIRP and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RPL26P34 RNA expression.
This table summarizes RPL26P34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL26P34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL26P34 shows lower tumor expression in BRCA and higher tumor expression in LUSC. The BRCA box plot shows higher RPL26P34 RNA expression in normal versus tumor tissue (log2 FC = −0.022, t-test p = .029).
This table shows molecular features associated with RPL26P34 in patient tissues and cancer cell lines. In patient samples, RPL26P34 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
